Bulking agent for female SUI offers durability at 2 years

March 25, 2010

A 2-year assessment of patients implanted with the urethral bulking agent Macroplastique (Uroplasty, Minnetonka, MN) for the treatment of female stress urinary incontinence showed that 84% of patients maintained significant improvement from their 12-month assessment.

A 2-year assessment of patients implanted with the urethral bulking agent Macroplastique (Uroplasty, Minnetonka, MN) for the treatment of female stress urinary incontinence showed that 84% of patients maintained significant improvement from their 12-month assessment.

Additionally, 67% of the patients were dry at the 24-month follow-up visit, researchers reported online in the Journal of Urology (Feb. 20, 2010).

The multicenter study followed 67 Macroplastique patients with successful outcomes at 12 months for up to 24 months. Of the 38 dry patients at 12 months, 87% maintained their cure at 24 months. Additionally, 41% of patients who were considered improved at 12 months were dry at 24 months.

"This long-term, multicenter study of Macroplastique demonstrated sustained results over 2 years," said first author Gamal Ghoniem, MD, of Cleveland Clinic Florida, Weston. "Using widely accepted outcome measures, we confirmed that patients sustained clinical improvements over a prolonged period of time. This positively impacted their quality of life and delayed the need for further treatment.

"This study further supports the strong scientific evidence of the effectiveness of Macroplastique for the treatment of stress urinary incontinence."

Dr. Ghoniem has disclosed financial interest and/or other relationship with Astellas, Uroplasty, and Coloplast.